Inventiva S.A. ADR (IVA) Stock Price, Quote & News

Company Profile

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. The company develops Lanifibranor, a novel pan-peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. It...

Industry: Biotechnology

Sector: Healthcare

Phone: 33 3 80 44 75 00

Website: inventivapharma.com

Address:

50 rue de Dijon, Daix, France

Quantumup May. 13 at 11:03 AM

Truist⬆️ $MDGL's PT to $709 and reiterated at a Buy rating after its survey work. $IVA $NVO ALGS VKTX SGMT LLY Truist said in its note: We are raising our PT to $709 from $640 following our survey work (link to publication) that reinforces our belief in the sizable MASH patient numbers eligible for treatment that will translate to significant Rezdiffra revenues. The survey work highlights physician preference for Rezdiffra as their choice for liver-targeted MASH agent, praise for Rezdiffra's safety profile, and desire for combination treatment that includes addition of Rezdiffra on to a background incretin. We are increasing the US peak (2036E) MASH patients treated with Rezdiffra to 193k, from 158k prior, that now reflects ~8,000 US F2/F3 pt adds per year, which may be conservative, in our view.

0 · Reply

S_Franconi May. 11 at 3:12 PM

$IVA Go Iva!!!

0 · Reply

BillionerOfKing Apr. 30 at 8:32 PM

$IVA Current Stock Price: $5.13 Contracts to trade: $5.0 IVA Nov 20 2026 Call Entry: $1.26 Exit: $1.80 ROI: 43% Hold ~20 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

Expharmaguy Apr. 30 at 8:00 PM

$IVA https://journals.lww.com/hep/fulltext/2025/12000/comparison_of_pharmacological_therapies_in.16.aspx According to this meta-analyses of 29 trials that enrolled >900 pts, Lanifibranor did not rank among the highest of the MASH drugs tested with respect to response rates. Did some DD and too many Red Flags. 1. Massive net lose of 354 Euros; 2. section on material uncertainty; 3. readout delays pushed to 4th quarter; 4. weigh gain associated with this class and did occur in the trials; 5. Contradictory trials timelines on their webcasts; 6. Co-Founder stepping back(why if BO is imminent) 7. Single drug in pipeline, so bet is binary; 8. low institutional investment. Opinion only. Do your own DD. I am not a short seller-invested in GALT, and SGMT but GALT targets a more advanced population(F4 with CSPH), while SGMT focus now is squarely on acne.

4 · Reply

POPEYE832 Apr. 30 at 5:33 AM

$IVA A really interesting article: https://www.nature.com/articles/s41586-026-10427-5

0 · Reply

BioTuesdays Apr. 27 at 4:09 PM

$IVA has appointed three new members to its leadership team, including Axel-Sven Malkomes as chief financial officer, Susan Coles as chief legal officer, and Pamela Herbster as chief people officer. https://biotuesdays.com/2026/04/27/inventiva-builds-c-suite-ahead-of-phase-3-mash-readout/

0 · Reply

Quantumup Apr. 23 at 3:34 PM

$IVA: pan-PPAR agonist Lanifibranor is under investigation in a Quintuple Agonist Study. $LLY $NVO Article Title: New quintuple agonist shows promise for treating obesity and type 2 diabetes: https://www.news-medical.net/news/20250921/New-quintuple-agonist-shows-promise-for-treating-obesity-and-type-2-diabetes.aspx

1 · Reply

Quantumup Apr. 23 at 2:58 PM

New *Quintuple Agonist data @ #ADA2026 in a Late Breaker Poster Session: Title: A Long-Acting Quintuple Agonist for the GLP-1, GIP, Glucagon, Amylin, and Calcitonin Receptors Induces Greater Weight Loss than Retatrutide in Obese Rats $LLY $NVO $IVA https://eppro02.ativ.me/web/planner.php?id=ADA26

1 · Reply

OfficialStocktwitsUser Apr. 22 at 5:07 PM

$IVA RSI: 48.89, MACD: -0.1339 Vol: 0.25, MA20: 5.54, MA50: 5.98 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

Jonita Apr. 22 at 11:37 AM

$IVA in in in

0 · Reply

Inventiva to Present Abstracts at the EASL Congress 2026

2026-04-22T20:16:11.000Z - 20 days ago

Inventiva CFO Jean Volatier to switch roles, Axel-Sven Malkomes to succeed

Apr 22, 2026, 4:00 PM EDT - 20 days ago

Market Cap	846.52M
Revenue (ttm)	8.97M
Net Income (ttm)	-400.67M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-4,466.78%
Debt to Equity Ratio	-2.10

Volume	70,646
Avg Vol	357,700
Day's Range	N/A - N/A
Shares Out	145.95M
Stochastic %K	72%
Beta	0.70
Analysts	Strong Sell
Price Target	$15.06